Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04862780 · ClinicalTrials.gov registry record · Phase 1
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
A Phase 1 study, sponsored by Blueprint Medicines Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 177
- Enrollment target
NCT04862780 is a Phase 1 study that was terminated before completion, run by Blueprint Medicines Corporation. The registered enrollment target is 177 participants.
The verdict
NCT04862780, a Phase 1 study, was terminated before completion, sponsored by Blueprint Medicines Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 177 participants
- Enrollment target
Study Summary
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-945, a selective EGFR inhibitor, as monotherapy or in combination with osimertinib.
Interventions
- DRUG osimertinib
- DRUG BLU-945
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 177 participants |
| Start Date | 2021-06-29 |
| Est. Completion | 2024-10-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04862780
The ClinicalTrials.gov registry entry for NCT04862780 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 177 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Blueprint Medicines Corporation, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which osimertinib is the first listed.
NCT04862780 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04862780 about?
NCT04862780 is a clinical study titled "(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC". This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-945, a selective EGFR inhibitor, as monotherapy or in combination with osimertinib.
What is the current status of trial NCT04862780?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 177 participants. The study started on 2021-06-29. Estimated completion is 2024-10-07.
What interventions are being tested in trial NCT04862780?
The interventions under investigation include: osimertinib (DRUG), BLU-945 (DRUG).
Who is sponsoring clinical trial NCT04862780?
This trial is sponsored by Blueprint Medicines Corporation, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.